为什么Scipher Medicine Corp.成功地在D系列融资中筹集了1.1亿美元，以进一步发展公司的Precision Medicine Platform。该公司旨在解决最现代医学最具挑战性的谜团之一：如何消除与处方昂贵的药物相关的成本和不利影响，这些药物为某些人提供了改变生活的结果，对其他人没有任何好处。新资金将Scipher的总资金提高到2.27亿美元，其中1.92亿美元在过去的12个月内进入了位于马萨诸塞州沃尔瑟姆的公司的金库。
Sangamo Therapeutics Inc. has reported preclinical results for IL23R-CAR-Tregs, a strategy based on chimeric antigen receptor (CAR)-modified regulatory T cells (Tregs) for the treatment of Crohn's disease.
日本卫生部、劳动和福利应用roved Takeda Pharmaceutical Co. Ltd.’s Alofisel (darvadstrocel) to treat complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease. This marks the first allogeneic stem cell therapy to be greenlighted in the country.
日本卫生部、劳动和福利应用roved Takeda Pharmaceutical Co. Ltd.’s Alofisel (darvadstrocel) to treat complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease. This marks the first allogeneic stem cell therapy to be greenlighted in the country.
Theravance Biopharma Inc.’s phase IIb fizzle with izencitinib in ulcerative colitis (UC) put a dent in shares, as Wall Street mulled the ongoing phase II study in Crohn’s disease (CD) as well as prospects regarding the deal with Johnson & Johnson.
